Oncolytics Biotech is a Canadian biotechnology company headquartered in Calgary, Alberta. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for cancer treatment.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant metastatic colorectal cancer, driving shares up 19.7%.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07446322 |
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer |
RECRUITING | PHASE2 |
| NCT07280377 |
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04445844 |
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04215146 |
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04102618 |
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer |
TERMINATED | EARLY_PHASE1 |
| NCT03605719 |
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma |
COMPLETED | PHASE1 |
| NCT03015922 |
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma |
UNKNOWN | PHASE1 |
| NCT02723838 |
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder |
WITHDRAWN | PHASE1 |
| NCT02620423 |
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma |
COMPLETED | PHASE1 |
| NCT02514382 |
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
COMPLETED | PHASE1 |
